Jasper Therapeutics (NASDAQ:JSPRW – Get Free Report) is expected to be posting its results before the market opens on Thursday, November 5th. Analysts expect Jasper Therapeutics to announce earnings of ($0.08) per share and revenue of $12.00 million for the quarter.
Jasper Therapeutics Stock Performance
Shares of NASDAQ JSPRW opened at $0.00 on Wednesday. Jasper Therapeutics has a fifty-two week low of $0.00 and a fifty-two week high of $0.15.
Jasper Therapeutics Company Profile
Jasper Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases involving hematopoietic stem cells, bone marrow transplantation and immune system disorders. The company’s research has centered on antibody-based medicines designed to enable or improve stem cell transplantation and gene therapy procedures.
Jasper’s leading investigational product is briquilimab, formerly known as JSP191. Briquilimab is a monoclonal antibody that targets CD117, a receptor involved in the survival and maintenance of hematopoietic stem cells.
Read More
- Five stocks we like better than Jasper Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
